Participated · Series C · Nov 2025

Hippocratic AI is a Palo Alto–based company building safety-focused generative AI agents for the healthcare sector. Its platform supplies non-diagnostic, patient-facing clinical agents intended to expand patient access and relieve administrative workload while rigorously adhering to a “do no harm” principle. In the 15 months since commercialization, the firm has forged partnerships with more than 50 health systems, payors, and pharmaceutical companies across six countries, created over 1,000 clinical use cases, and completed 115 million patient interactions without safety incidents. Notable collaborators include Cleveland Clinic, Northwestern Medicine, Cincinnati Children’s Hospital, WellSpan Health, and several of the top U.S. payors. The company’s Polaris Safety Constellation architecture underpins its emphasis on empathy, reliability, and clinical alignment. New capital will support expanded global deployments, continued product innovation, and selective M&A activity. The latest raise lifts total funding to $404 million and pegs the company’s valuation at $3.5 billion.

Participated · Series C · Jan 2022

Enable Injections is a Cincinnati, OH-based healthcare company focused on improving the patient treatment experience with its enFuse On-Body Delivery System (OBDS), which enables subcutaneous administration of large-volume drugs. The technology aims to replace lengthy intravenous infusions with a discreet, wearable device that patients can use outside clinical settings. To scale production, the company announced plans in February 2024 for a 90,000-square-foot Manufacturing Center of Excellence in Springdale, Ohio, alongside upgrades to its Evendale headquarters. Enable Injections closed a $215 million Series C round in January 2022 led by Magnetar Capital, with participation from Sanofi and other institutional and regional investors. In January 2026, Sanofi committed an additional $30 million, underscoring strategic support for the commercialization of enFuse. The new capital will be used to consolidate supply-chain capabilities and accelerate commercial growth. These funds position Enable Injections to advance toward full-scale manufacturing and market launch of its OBDS platform.

Participated · Convertible Note · Mar 2017

Airway Therapeutics is developing a new class of biologics to break the injury cycle of inflammation for patients with respiratory and inflammatory diseases. The company is advancing AT-100 (rhSP-D), a recombinant human protein engineered to reduce inflammation and infection while modulating the immune response. AT-100 has received Orphan Drug Designation from both the U.S. Food and Drug Administration and the European Medicines Agency. Preclinical BPD research showed AT-100 prevented the onset of lung tissue damage and reduced inflammation and infection triggered by mechanical ventilation and oxygen support. Airway intends to use the financing to advance clinical development of AT-100 as a preventive treatment for bronchopulmonary dysplasia (BPD) in very preterm infants and to support preclinical work in influenza, RSV and cystic fibrosis. The company recently hired Alan S. Wolk as Chief Financial and Operating Officer and Uday Patel as Vice President of Regulatory Affairs and Quality. Airway Therapeutics develops a protein replacement therapy, AT-100, aimed at preventing and treating lung disease in vulnerable patients, beginning with premature infants. The company is based in Sharonville, Ohio, and is led by CEO Marc Salzberg with Paul V. Remsen as Vice President of Manufacturing. Airway has patent protection for its work and has received orphan designation status for AT-100 in bronchopulmonary dysplasia (BPD) in the US and the European Union, which provides a 7 and 12 year market exclusivity. The company recently secured $6.3M in bridge financing. Airway intends to use the funds to continue development of AT-100. The financing and regulatory incentives position the company to advance clinical development of its lead program. Airway Therapeutics is a Sharonville, Ohio-based biotechnology company focused on preventing bronchopulmonary dysplasia (BPD) in extremely premature infants. Its lead product, AT-100, is a recombinant human surfactant protein D intended to be used in addition to commercial surfactant to prevent infection and lung damage. Pre-clinical data reported by the company suggest AT-100 more effectively prevents infection and lung injury than the current standard of care. Both the US Food and Drug Administration and European regulators have granted AT-100 orphan designation. Led by CEO Marc Salzberg, MD, the company intends to use its recent financing to continue development of AT-100.

Participated · Series D · Dec 2015

Assurex Health offers GeneSight, a treatment-decision-support test powered by CPGx™, its proprietary combinatorial pharmacogenomics technology, which measures multiple genomic variants and weights them together to provide genetically-driven medication information for each patient. The company recently enhanced the GeneSight Psychotropic test to give providers an expanded range of options for treating depression, anxiety, bipolar disorder, PTSD, schizophrenia and other behavioral health conditions. To date more than 14,000 healthcare providers have used GeneSight to help make treatment decisions for over 230,000 patients across the country. Led by President and CEO Virginia C. Drosos, Assurex will use additional funding to continue to increase adoption of GeneSight. The company also serves chronic pain conditions through its treatment decision support offerings. Assurex Health provides healthcare providers with GeneSight, a treatment decision‑support platform that analyzes how a patient’s genetics affect responses to medications for behavioral health and chronic pain. GeneSight evaluates a patient’s cheek swab against over 785,000 genetic–medication permutations and reports on 38 FDA‑approved medications across depression, PTSD, bipolar disorder, schizophrenia and other mental health conditions. Results are delivered in an actionable color‑coded report available 36 hours after Assurex receives a patient sample. The company also offers financial assistance programs for eligible patients. Led by President and CEO Virginia C. Drosos, Assurex is using proceeds from a $30M equity financing to support increased clinical adoption and further development of its GeneSight products. Assurex Health is a Mason, OH–based personalized medicine company that provides clinically-relevant individualized genetic information to help physicians select medications for depression, anxiety, chronic pain, ADHD and other neuropsychiatric disorders. Its core product is the GeneSight® suite, built on proprietary pharmacogenomics technology combined with evidence-based medicine and clinical pharmacology. The company has licensed patented technology from Mayo Clinic and Cincinnati Children’s Hospital Medical Center. Led by CEO James S. Burns, Assurex intends to use the proceeds from its financing to support increasing clinical adoption of its GeneSight products. The company secured a $32M financing comprising a $25M term and revolving credit facility and a $7M equity financing from existing investors.

Participated · Series B · Jan 2015

Claritas Genomics provides clinical genetic diagnostic testing using next-generation sequencing and a network of pediatric disease specialists to support clinicians. The company combines clinical expertise of pediatric specialists with sequencing technology to offer a range of diagnostic services. It plans to expand commercial operations and launch new sequencing-based tests for diagnosis of pediatric genetic disorders. Claritas also intends to continue building its network of clinical pediatric disease experts. The company is led by CEO Patrice Milos, Ph.D.